drugset / Trial / NCT04807829
Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Suicide is a major crisis worldwide with rates projected to continue to increase. There is currently a dearth of novel pharmacologic treatment options for suicide available on the market. The endocannabinoid system has been recently shown to be associated with mood disorders including suicidality. The aim of the study is to determine whether treatment with Nabilone is capable of reducing suicidal ideation in adults after 3 days.
Timeline
- Start
- 2021-04
- Primary completion
- 2022-04
- Completion
- 2022-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nabilone | Other / unclassified | 2 mg | Oral |
Indications
No indication recorded.